142 related articles for article (PubMed ID: 33054935)
1. Upcoming topical TRPV1 anti-pruritic compounds.
Lee KP; Koshelev MV
Dermatol Online J; 2020 Sep; 26(9):. PubMed ID: 33054935
[TBL] [Abstract][Full Text] [Related]
2. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases.
Lim KM; Park YH
Arch Pharm Res; 2012 Mar; 35(3):393-6. PubMed ID: 22477184
[TBL] [Abstract][Full Text] [Related]
3. Itch Management: Treatments under Development.
Pereira MP; Ständer S
Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
[TBL] [Abstract][Full Text] [Related]
4. Drugs on the Horizon for Chronic Pruritus.
McEwen MW; Fite EM; Yosipovitch G; Patel T
Dermatol Clin; 2018 Jul; 36(3):335-344. PubMed ID: 29929605
[TBL] [Abstract][Full Text] [Related]
5. A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers.
Gibson RA; Robertson J; Mistry H; McCallum S; Fernando D; Wyres M; Yosipovitch G
PLoS One; 2014; 9(7):e100610. PubMed ID: 25047038
[TBL] [Abstract][Full Text] [Related]
6. Topical capsaicin. The fire of a 'hot' medicine is reignited.
Papoiu AD; Yosipovitch G
Expert Opin Pharmacother; 2010 Jun; 11(8):1359-71. PubMed ID: 20446852
[TBL] [Abstract][Full Text] [Related]
7. Activation of Transient Receptor Potential Vanilloid-3 Channels in Keratinocytes Induces Pruritus in Humans.
Kim JC; Kim HB; Shim WS; Kwak IS; Chung BY; Kang SY; Park CW; Kim HO
Acta Derm Venereol; 2021 Aug; 101(8):adv00517. PubMed ID: 34184069
[TBL] [Abstract][Full Text] [Related]
8. Application of an 8% capsaicin patch normalizes epidermal TRPV1 expression but not the decreased intraepidermal nerve fibre density in patients with brachioradial pruritus.
Pereira MP; Lüling H; Dieckhöfer A; Steinke S; Zeidler C; Agelopoulos K; Ständer S
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1535-1541. PubMed ID: 29427475
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of TRPV1 channels by a naturally occurring omega-9 fatty acid reduces pain and itch.
Morales-Lázaro SL; Llorente I; Sierra-Ramírez F; López-Romero AE; Ortíz-Rentería M; Serrano-Flores B; Simon SA; Islas LD; Rosenbaum T
Nat Commun; 2016 Oct; 7():13092. PubMed ID: 27721373
[TBL] [Abstract][Full Text] [Related]
10. Anti-pruritic and anti-inflammatory effects of natural verbascoside through selective inhibition of temperature-sensitive Ca
Sun X; Qi H; Wu H; Qu Y; Wang K
J Dermatol Sci; 2020 Mar; 97(3):229-231. PubMed ID: 31983608
[No Abstract] [Full Text] [Related]
11. Anti pruritic effects of topical crotamiton, capsaicin, and a corticosteroid on pruritogen-induced scratching behavior.
Sekine R; Satoh T; Takaoka A; Saeki K; Yokozeki H
Exp Dermatol; 2012 Mar; 21(3):201-4. PubMed ID: 22379965
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.
Lee YW; Won CH; Jung K; Nam HJ; Choi G; Park YH; Park M; Kim B
Br J Dermatol; 2019 May; 180(5):1030-1038. PubMed ID: 30623408
[TBL] [Abstract][Full Text] [Related]
13. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).
Lee Y; Hong S; Cui M; Sharma PK; Lee J; Choi S
Expert Opin Ther Pat; 2015 Mar; 25(3):291-318. PubMed ID: 25666693
[TBL] [Abstract][Full Text] [Related]
14. Emerging Treatments and Novel Pathways in Pruritus.
Besner Morin C; Misery L
J Cutan Med Surg; 2019; 23(5):528-536. PubMed ID: 31167547
[TBL] [Abstract][Full Text] [Related]
15. TRPV1 and PLC Participate in Histamine H4 Receptor-Induced Itch.
Jian T; Yang N; Yang Y; Zhu C; Yuan X; Yu G; Wang C; Wang Z; Shi H; Tang M; He Q; Lan L; Wu G; Tang Z
Neural Plast; 2016; 2016():1682972. PubMed ID: 26819760
[TBL] [Abstract][Full Text] [Related]
16. Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models.
Yun JW; Seo JA; Jang WH; Koh HJ; Bae IH; Park YH; Lim KM
J Invest Dermatol; 2011 Jul; 131(7):1576-9. PubMed ID: 21471988
[No Abstract] [Full Text] [Related]
17. Topical Application of ASN008, a Permanently Charged Sodium Channel Blocker, Shows Robust Efficacy, a Rapid Onset, and Long Duration of Action in a Mouse Model of Pruritus.
Ramachandran R; Thompson SK; Malkmus S; Mieda T; Lin JH; Gupta S; Yaksh TL
J Pharmacol Exp Ther; 2020 Sep; 374(3):521-528. PubMed ID: 32616515
[TBL] [Abstract][Full Text] [Related]
18. TRPV1-mediated itch in seasonal allergic rhinitis.
Alenmyr L; Högestätt ED; Zygmunt PM; Greiff L
Allergy; 2009 May; 64(5):807-10. PubMed ID: 19220220
[TBL] [Abstract][Full Text] [Related]
19. Transient Receptor Potential Channels and Itch.
Mahmoud O; Soares GB; Yosipovitch G
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613861
[TBL] [Abstract][Full Text] [Related]
20. Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders.
Serafini M; Griglio A; Aprile S; Seiti F; Travelli C; Pattarino F; Grosa G; Sorba G; Genazzani AA; Gonzalez-Rodriguez S; Butron L; Devesa I; Fernandez-Carvajal A; Pirali T; Ferrer-Montiel A
J Med Chem; 2018 May; 61(10):4436-4455. PubMed ID: 29722529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
